Q&A with Seth Karol, MD: Treating Pediatric Osteonecrosis
Seth Karol, MD, St. Jude's Children's Research Center and his team focused their research on the 10-20 age group, the "sweet spot" where the bones are still finishing up development and thus going to be susceptible to therapy.
Seth Karol, MD, St. Jude's Children's Research Center and his team focused their research on the 10-20 age group, the "sweet spot" where the bones are still finishing up development and thus going to be susceptible to therapy.
"The more we know about the biology of the cancer we're trying to treat, the better we can try to separate the toxicity to the patient from the toxicity to the cancer, which is what we're aiming for," concluded Karol.
Related Videos
Related Content
